SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-19-009968
Filing Date
2019-08-05
Accepted
2019-08-05 16:22:41
Documents
61
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20190630x10q.htm   iXBRL 10-Q 1361319
2 EXHIBIT 10.1 mrtx063019ex101-amende.htm EX-10.1 202198
3 EXHIBIT 31.1 mrtx063019ex311.htm EX-31.1 12407
4 EXHIBIT 31.2 mrtx063019ex312.htm EX-31.2 12871
5 EXHIBIT 32.1 mrtx063019ex321.htm EX-32.1 8231
  Complete submission text file 0001628280-19-009968.txt   5148909

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20190630.xsd EX-101.SCH 30565
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20190630_cal.xml EX-101.CAL 49822
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20190630_def.xml EX-101.DEF 117489
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20190630_lab.xml EX-101.LAB 390048
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20190630_pre.xml EX-101.PRE 223877
11 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20190630x10q_htm.xml XML 802165
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 19998938
SIC: 2834 Pharmaceutical Preparations